Literature DB >> 33238089

Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.

Daniel J Smith1, Paul R Ellis1, Alice M Turner1,2.   

Abstract

Alpha-1 antitrypsin deficiency (AATD) is an important risk factor for development of chronic obstructive pulmonary disease (COPD). Patients with AATD classically develop a different pattern of lung disease from those with usual COPD, decline faster and exhibit a range of differences in pathogenesis, all of which may be relevant to phenotype and/or impact of exacerbations. There are a number of definitions of exacerbation, with the main features being worsening of symptoms over at least 2 days, which may be associated with a change in treatment. In this article we review the literature surrounding exacerbations in AATD, focusing, in particular, on ways in which they may differ from such events in usual COPD, and the potential impact on clinical management. JCOPDF
© 2021.

Entities:  

Keywords:  Alpha-1 antitrypsin deficiency; Chronic obstructive pulmonary disease; Emphysema; Exacerbation; Neutrophil

Year:  2021        PMID: 33238089      PMCID: PMC8047608          DOI: 10.15326/jcopdf.2020.0173

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  127 in total

1.  Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties.

Authors:  N V Rao; N G Wehner; B C Marshall; W R Gray; B H Gray; J R Hoidal
Journal:  J Biol Chem       Date:  1991-05-25       Impact factor: 5.157

2.  Critical role of calpain in inflammation.

Authors:  Jingjing Ji; Lei Su; Zhifeng Liu
Journal:  Biomed Rep       Date:  2016-10-19

3.  Assessment of airway neutrophils by sputum colour: correlation with airways inflammation.

Authors:  R A Stockley; D Bayley; S L Hill; A T Hill; S Crooks; E J Campbell
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

4.  The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity.

Authors:  David A Bergin; Emer P Reeves; Killian Hurley; Rebecca Wolfe; Ramia Jameel; Sean Fitzgerald; Noel G McElvaney
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

5.  The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.

Authors:  Robert A Stockley; Darren L Bayley; Ipek Unsal; Lee J Dowson
Journal:  Am J Respir Crit Care Med       Date:  2002-06-01       Impact factor: 21.405

6.  Relationship between airway colonization, inflammation and exacerbation frequency in COPD.

Authors:  Munir Tumkaya; Sibel Atis; Cengiz Ozge; Nuran Delialioglu; Gurbuz Polat; Arzu Kanik
Journal:  Respir Med       Date:  2006-09-26       Impact factor: 3.415

7.  Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8.

Authors:  I S Woolhouse; D L Bayley; R A Stockley
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

8.  Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant.

Authors:  Alan T Mulgrew; Clifford C Taggart; Matthew W Lawless; Catherine M Greene; Mark L Brantly; Shane J O'Neill; Noel G McElvaney
Journal:  Chest       Date:  2004-05       Impact factor: 9.410

9.  Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.

Authors:  Henrik Watz; Kay Tetzlaff; Emiel F M Wouters; Anne Kirsten; Helgo Magnussen; Roberto Rodriguez-Roisin; Claus Vogelmeier; Leonardo M Fabbri; Pascal Chanez; Ronald Dahl; Bernd Disse; Helen Finnigan; Peter M A Calverley
Journal:  Lancet Respir Med       Date:  2016-04-07       Impact factor: 30.700

10.  Changes in forced expiratory volume in 1 second over time in COPD.

Authors:  Jørgen Vestbo; Lisa D Edwards; Paul D Scanlon; Julie C Yates; Alvar Agusti; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William MacNee; Bruce E Miller; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Stephen I Rennard
Journal:  N Engl J Med       Date:  2011-09-26       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.